ResMed Upgraded by S&P Equity Research to “Buy” (RMD)
Shares of ResMed opened at 44.49 on Wednesday. ResMed has a one year low of $28.94 and a one year high of $48.47. The stock’s 50-day moving average is currently $44.34. The company has a market cap of $6.384 billion and a P/E ratio of 22.42.
The company also recently declared a quarterly dividend, which is scheduled for Tuesday, March 19th. Investors of record on Tuesday, February 19th will be given a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a yield of 1.53%. The ex-dividend date of this dividend is Thursday, February 14th.
RMD has been the subject of a number of other recent research reports. Analysts at BMO Capital Markets raised their price target on shares of ResMed to $48.00 in a research note to investors on Friday, January 25th. They now have a market perform rating on the stock. Separately, analysts at Jefferies Group reiterated a hold rating on shares of ResMed in a research note to investors on Friday, January 25th. They now have a $42.00 price target on the stock, up previously from $35.00. Finally, analysts at Bank of America downgraded shares of ResMed from a buy rating to a neutral rating in a research note to investors on Friday, January 25th.
Nine analysts have rated the stock with a buy rating, one has assigned an overweight rating, and thirteen have assigned a hold rating to the company. The company currently has a consensus rating of overweight and an average price target of $47.94.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.